NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$18.60

11 Sep
2025

-1.500

OPEN

$19.69

-7.46%

HIGH

$19.80

1,220,129

LOW

$18.10

TARGET
$24.70 32.8% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 111.2 14.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 10.1% - 87.1% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 134.3 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx111.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx213.2 M
Book Value Per Share xxxxxxxxxxxxxxx286.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.3 M
Net Profit Margin xxxxxxxxxxxxxxx66.61 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx49.92 %
Return on Invested Capital xxxxxxxxxxxxxxx49.92 %
Return on Assets xxxxxxxxxxxxxxx43.20 %
Return on Equity xxxxxxxxxxxxxxx49.92 %
Return on Total Capital xxxxxxxxxxxxxxx61.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx222 M
Price To Book Value xxxxxxxxxxxxxxx4.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx38 M
Research & Development xxxxxxxxxxxxxxx33 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

28/08/2025

1

Buy

$22.00

18.28%

Neuren Pharmaceuticals' interim revenue of $28.3m rose by 16% year-on-year, in line with pre-released figures, derived entirely from royalties on Daybue sales.

Earnings beat Bell Potter’s forecasts due to a lower R&D expense and a $5.2m currency benefit. Cash at June 30 stood at $300m following a $50m buyback, with interest income of $6.3m more than covering corporate costs.

Neuren is expected to receive $62-67m in royalties in 2025 (bell Potter forecasts $64m) based on Acadia’s Daybue sales guidance.

While R&D spend will increase in the second half as Phase 3 trials progress, royalty and interest income should ensure another profitable year, suggest the analysts. A potential $50m milestone payment in 2026 tied to EU approval would further strengthen the balance sheet.

The broker retains a Buy rating with a $22.00 target price.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 13.80 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 32.30 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

13/08/2025

1

Buy

$28.12

51.18%

Acadia announced Daybue sales in 2Q2025 of US$96.1m, or growth of 14% on the prior year, due to a rise in patient use and sustained user “persistency” rates, explains Canaccord Genuity. Guidance for 2025 was retained.

Neuren Pharmaceuticals' royalty income of $14.7m rose 16% annually, and Acadia's guidance infers royalty income of $62m-$67m for 2025.

Positively, the rate of persistency is on the rise, with 70% of patients on therapy having been treated for at least a year, up from 65% at the last update.

Acadia points to EU approval being in line for 1Q2026, and the first EU commercial sale would represent a milestone for Neuren — a US$35m payment. Buy rated with an unchanged $28.12 target price.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 17.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 61.00 cents.

Petra Capital

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More

Sep 04 2025 - Rudi's View
2
Australian Broker Call *Extra* Edition – Sep 03, 2025

Sep 03 2025 - Daily Market Reports
3
FNArena Corporate Results Monitor – 28-08-2025

Aug 28 2025 - Australia
4
Rudi’s View: BlueScope Steel, IGO, GrainCorp, Pilbara Minerals, Santos & More

Aug 14 2025 - Rudi's View
5
Australian Broker Call *Extra* Edition – Aug 13, 2025

Aug 13 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
2
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
3
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
4
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
5
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
6
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
7
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
8
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
9
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
10
CSL Shares Breaking Free

Jul 23 2024 - Technicals